Skip to main content
ENERGENESIS logo

ENERGENESIS — Investor Relations & Filings

Ticker · 6657 ISIN · TW0006657000 TW Professional, scientific and technical activities
Open in API
Filings indexed 37 across all filing types
Latest filing 2026-06-01 Governance Information
Country TW Taiwan
Listing TW 6657

About ENERGENESIS

http://www.energenesis-biomedical.com

Energenesis Biomedical Co., Ltd. specializes in the research and development of innovative pharmaceuticals through its proprietary ENERGI drug development platform. The company focuses on the activation of AMP-activated protein kinase (AMPK), a critical enzyme for cellular energy regulation, to develop therapeutic solutions for various diseases. Its core pipeline centers on small molecule purine compounds designed to modulate cellular energy metabolism. Operating with an intellectual property-driven strategy, the company manages the development cycle from early-stage drug discovery through clinical trial validation. Energenesis Biomedical aims to increase the value of its proprietary technologies for strategic out-licensing and collaboration with global pharmaceutical partners. In addition to drug development, the company offers specialized testing and analysis services and distributes research reagents.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_6657_20260522F14.pdf
Governance Information Classification · 92% confidence The document is an internal “取得或處分資產處理程序” (Asset Acquisition or Disposal Procedure) manual of the company, detailing the internal rules, authority levels, board and audit committee approval processes, definitions, and governance controls for asset transactions. It is not a financial report, announcement, or filing of results, but rather a set of corporate governance policies. Therefore, it fits the Governance Information (CGR) category.
2026-06-01 Chinese
115年年報及股東會資料 — 2026_6657_20260522F05.pdf
AGM Information Classification · 93% confidence The document is the detailed minutes (議事錄) of the company’s Annual General Meeting, listing attendance, agenda items, reports, proposed resolutions, shareholder questions, voting results for each proposal, and adjournment. It is not a financial report, earnings release, proxy, or regulatory announcement but the full record of the AGM proceedings. Therefore it falls under AGM Information (AGM-R).
2026-06-01 Chinese
114年度股利金額(董事會決議)
Notice of Dividend Amount Classification · 90% confidence The document is a dividend distribution table provided by the company, detailing cash and stock dividend per share, distribution dates, board and shareholder meeting decisions, and related notes. This matches the definition of a Notice of Dividend Amount (announcement of dividend amounts, payment dates, and details for shareholders).
2026-05-22 Chinese
115年第1季財務報告書 — 202601_6657_AI1.pdf
Interim / Quarterly Report Classification · 96% confidence The document is titled “合併財務報告暨會計師核閱報告 民國115及114年第1季” and contains complete interim financial statements (consolidated balance sheet, income statement, cash flows, changes in equity, and detailed notes) along with an auditor’s review opinion under IFRS IAS 34 for the first quarter periods. This is clearly a substantive interim/quarterly financial report, not merely an announcement or summary. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-13 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 80% confidence The document is from the public information observatory (“公開資訊觀測站”) and is titled “115年1季申報作業,” i.e. Q1 reporting work. It contains actual financial data—investment balances, recognized profit/loss—for the quarter. This aligns with an Interim / Quarterly Report (IR), as it is substantive financial data for a period shorter than a full fiscal year. It is not merely an announcement or a link to a report, but the report content itself. Q1 2026
2026-05-11 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 90% confidence The document is titled “合併權益變動表” (Consolidated Statement of Changes in Equity) and contains actual financial line‐item data for the first quarter of the fiscal year (對比去年同期). This is a standalone financial statement for a period shorter than a full fiscal year, which matches the definition of an Interim/Quarterly Report. It is not merely an announcement or a link to a report, but includes substantive numerical disclosures. Q1 2026
2026-05-11 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.